Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Mouse (Murine) Antikörper:
anti-Rat (Rattus) Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal LAG3 Primary Antibody für FACS, ICC - ABIN4329753
Casati, Camisaschi, Novellino, Mazzocchi, Triebel, Rivoltini, Parmiani, Castelli: Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation. in Journal of immunology (Baltimore, Md. : 1950) 2008
Show all 13 Pubmed References
Human Monoclonal LAG3 Primary Antibody für FACS - ABIN4329756
Demeure, Wolfers, Martin-Garcia, Gaulard, Triebel: T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. in European journal of cancer (Oxford, England : 1990) 2001
Show all 10 Pubmed References
Human Polyclonal LAG3 Primary Antibody für FACS - ABIN4896615
Melve, Ersvaer, Akkök, Ahmed, Kristoffersen, Hervig, Bruserud: Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor. in International journal of molecular sciences 2016
Show all 9 Pubmed References
Human Monoclonal LAG3 Primary Antibody für FACS, Func - ABIN1169105
Hannier, Tournier, Bismuth, Triebel: CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. in Journal of immunology (Baltimore, Md. : 1950) 1998
Show all 8 Pubmed References
Mouse (Murine) Monoclonal LAG3 Primary Antibody für BR, FACS - ABIN1176990
Huang, Workman, Flies, Pan, Marson, Zhou, Hipkiss, Ravi, Kowalski, Levitsky, Powell, Pardoll, Drake, Vignali: Role of LAG-3 in regulatory T cells. in Immunity 2004
Show all 6 Pubmed References
Human Polyclonal LAG3 Primary Antibody für CyTOF, FACS - ABIN4899757
Porichis, Kwon, Zupkosky, Tighe, McMullen, Brockman, Pavlik, Rodriguez-Garcia, Pereyra, Freeman, Kavanagh, Kaufmann: Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. in Blood 2011
Show all 5 Pubmed References
Human Monoclonal LAG3 Primary Antibody für Func, ICC - ABIN1169112
Huard, Gaulard, Faure, Hercend, Triebel: Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. in Immunogenetics 1994
Show all 4 Pubmed References
Human Monoclonal LAG3 Primary Antibody für BP, ELISA - ABIN4329755
Triebel, Hacene, Pichon: A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. in Cancer letters 2006
Show all 3 Pubmed References
Mouse (Murine) Monoclonal LAG3 Primary Antibody für FACS - ABIN2479314
Dover, Escobar, Dueñas, Leal: Pneumonia associated with measles. in JAMA 1975
Show all 4 Pubmed References
Mouse (Murine) Monoclonal LAG3 Primary Antibody für FACS - ABIN2479316
Workman, Rice, Dugger, Kurschner, Vignali: Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). in European journal of immunology 2002
Show all 4 Pubmed References
PD-1 and LAG-3 cooperatively mediate the functional exhaustion of CD4(+) and CD8(+) T cells and are associated with the development of B-cell lymphoma in BLV-infected cattle.
molecular cloning and expression in bovine leukemia virus infection
We show that the expression of LAG3 is highly induced in the lungs and particularly in the granulomatous lesions of macaques experimentally infected with mycobacterium tuberculosis.
Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
findings demonstrate that LAG-3 regulates the specificity of immune response by its structural conformation-dependent recognition of pMHCII
A natural plasma cell subset expressing the inhibitory receptor LAG-3 is developed from various B cell subsets in a B cell receptor-dependent manner. After challenge they upregulate IL-10 expression via a Toll-like receptor-driven mechanism. This function is associated with a unique transcriptome and epigenome, including the lowest amount of DNA methylation at the Il10 locus compared to other B cell subsets.
upregulated in the central nervous system by intraepithelial lymphocytes from the gut epithelium of myelin oligodendrocyte glycoprotein(35-55)-specific T-cell receptor transgenic mice
thi study shows that LAG-3 directly modulates the size of the T cell response and support the use of LAG-3 blockade regimens to enhance CD8+ T cell responses
Study suggests that expression of the inhibitory receptors PD-1 and LAG-3 on CD4(+) T cells and their reduced IL-2 production are common characteristic features of Plasmodium infection.
An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy.
LAG3 and PD1 co-inhibitory molecules have roles in collaborating to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.
Lymphatic endothelial cells (LECs) serve as an antigen reservoir for CD4 T-cell tolerance, and MHC-II molecules on LECs are used to induce CD8 T-cell tolerance via LAG-3.
LAG-3 expression on Tconv cells makes them more susceptible to Treg based suppression, and also regulates the development of a TH1 T-cell response.
LAG-3 exerts an important regulatory effect on autoimmunity.
Lag-3 is an important regulatory molecule involved in alloreactive T cell proliferation and activation after bone marrow transplantation.
these results define a strong synergy between the PD-1 and LAG-3 inhibitory pathways in tolerance to both self and tumor antigens.
We conclude that LAG-3 is necessary for regulating CD4(+) and CD8(+) T cell function during autoimmune diabetes
LAG-3 is required for long-term peripheral CD8 but not CD4 T-cell tolerance and this requirement is CD8 cell-extrinsic.
LAG-3 acts synergistically with PD-1 and/or other immunoregulatory genes to prevent autoimmunity in mice.
This significant intracellular storage of LAG-3 appears to facilitate its rapid translocation to the cell surface following T-cell activation, which was much faster for LAG-3 than CD4
blockade of LAG-3 did not rescue cytokine production by virus-specific CD8 T cells and did not alter the virus titer in various organs
Lag3 inhibits CD4-dependent, but not CD4-independent, T cell function via its cytoplasmic domain.
Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients
PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
HIV induced upregulation of LAG-3 singly or in combination with PD1 in immune cells may regulate cardiac health
Based on these findings, we conclude that sLAG3 positively regulates CD8+T cells, IL-12 and IFN-gamma, and function as a prognostic marker for Gastric cancer (GC), which might be a potential target in the treatment of GC
This study identify LAG3 genes with expression patterns that are highly significant predictors of regional brain atrophy.
Results demonstrated that the expression of LAG3 in colorectal carcinoma tissue was significantly increased compared with the paracancerous tissue. It was mainly expressed at the edge of tumor tissues suggesting that LAG3 was expressed on tumorinfiltrating lymph node cells but not in colorectal cancer cells.
These results together suggested that LAG-3 is a marker of CD4(+) T cells with regulatory function; at the same time, LAG-3 might have limited the full suppressive potential of Treg cells.
Among the 89 patients, CD274, LAG3, and IDO1 expressions in TIICs were observed in 68.6% (61 cases), 13.5% (12), and 28.1% (25) of patients, respectively. CD274, CTLA4, and IDO1 were expressed in tumor cells of 24.7% (22 cases), 4.5% (4), and 72.0% (64) of patients, respectively.
LAG-3+ iTILs are enriched in estrogen receptor-negative breast cancers and represent an independent favorable prognostic factor. In addition, a high proportion of PD-1/PD-L1+ tumors are co-infiltrated with LAG-3+ TILs.
Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Data suggest that blocking LAG3-MHC class II interactions is a potential therapeutic target in chronic lymphocytic leukemia.
LAG-3 expression was correlated with expression of PD-1 on TILs and expression of PD-L1 on tumor cells. Higher expression of LAG-3 on TILs was significantly correlated with higher expression of PD-1 on TILs and higher expression of PD-L1 on tumor cells.
the upregulation of others syncytial molecules, including LAG3, CTLA4, CD28 and CD3, assisting the formation of syncytia with APC cells.
LAG3-expressing CD4(+)CD25(-) T cells represent another regulatory immune cell type with potential to interfere with anti-tumor immunity.
Overexpression of lymphocyte activation gene-3 inhibits regulatory T cell responses in osteoarthritis
Egr2-driven cell surface proteins LAG-3 and 4-1BB can identify dysfunctional tumor antigen-specific CD8(+) TIL.
our data indicate that the evaluation of stromal TILs remains the most reliable immune prognostic marker in TNBC, and support the clinical evaluation of anti-PD-1/PD-L1 and anti-LAG-3 in a subset of patients with TNBC who have concurrent expression of both checkpoint receptors.
this review provides the translational rationale for targeting LAG3, as well as historical and current state of clinical trials utilizing LAG3 cancer immunomodulators
this study shows that LAG3 expressed on myeloid leukaemia cells possess the capacity to facilitate functional exhaustion in T helper cells
Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4.
lymphocyte-activation gene 3
, lymphocyte-activation protein 3
, lymphocyte-activation protein 3-like
, lymphocyte activation gene 3 protein-like
, lymphocyte activation gene 3 protein
, lymphocyte activation gene 3